Volume 96, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Toll-like receptors (TLRs) are recognized as fundamental contributors to the immune system function against infections. Hepatitis C virus (HCV) infection represents a global health problem especially in Egypt having the highest HCV prevalence worldwide where HCV infection is a continuing epidemic. The aim of the present study was to investigate the possible association between genetic variation in TLR-3 and TLR-9 and HCV infection and hepatic fibrosis in chronic HCV-positive Egyptian patients. The present study included 100 naïve chronic HCV-positive patients and 100 age- and sex-matched healthy controls. Genotyping of TLR-3 (_7 C/A [rs3775296]), TLR-3 (c.1377C/T [rs3775290]) and TLR-9 (1237T/C [rs5743836]) were done by polymerase chain reaction restriction fragment length polymorphism technique. Frequency of polymorphic genotypes in TLR-3 (_7 C/A), TLR-3 (c.1377C/T) and TLR-9 (1237T/C) were not significantly different between studied HCV-positive patients and controls with values 0.121, 0.112, and 0.683, respectively. TLR-3 c.1377 T-allele was associated with advanced stage of hepatic fibrosis ( = 0.003).


Article metrics loading...

Loading full text...

Full text loading...



  1. El-Zanaty F, Way A, , 2009. Egypt Demographic and Health Survey 2008. Cairo, Egypt: Ministry of Health, El Zanaty and Associates, and Macro International. Available at: http://dhsprogram.com/pubs/pdf/FR220/FR220.pdf. Accessed May 17, 2013.
  2. Visvanathan K, Lewin SR, , 2006. Immunopathogenesis: role of innate and adaptive immune responses. Semin Liver Dis 26: 104115.[Crossref]
  3. Bertoletti A, Gehring AJ, , 2006. The immune response during hepatitis B virus infection. J Gen Virol 87: 14391449.[Crossref]
  4. Akira S, Takeda K, , 2004. Toll-like receptor signaling. Nat Rev Immunol 4: 499511.[Crossref]
  5. Isaza-Correa JM, Liang Z, van den Berg A, Diepstra A, Visser L, , 2014. Toll-like receptors in the pathogenesis of human B cell malignancies. J Hematol Oncol 7: 57.[Crossref]
  6. O'Neill LA, Bowie AG, , 2007. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7: 353364.[Crossref]
  7. Krishnegowda G, Hajjar AM, Zhu J, Douglass EJ, Uematsu S, Akira S, Woods AS, Gowda DC, , 2005. Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J Biol Chem 280: 86068616.[Crossref]
  8. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S, , 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740745.[Crossref]
  9. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S, , 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3: 196200.[Crossref]
  10. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, Raz E, Cottam HB, , 2003. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA 100: 66466651.[Crossref]
  11. Heil F, Ahmad-Nejad P, Hemmi H, Hochrein H, Ampenberger F, Gellert T, Dietrich H, Lipford G, Takeda K, Akira S, Wagner H, Bauer S, , 2003. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 33: 29872997.[Crossref]
  12. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA, , 2001. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413: 732738.[Crossref]
  13. Ahmad-Nejad P, Häcker H, Rutz M, Bauer S, Vabulas RM, Wagner H, , 2002. Bacterial CpG-DNA and lipopolysaccharidesactivate Toll-like receptors at distinct cellular compartments. Eur J Immunol 32: 19581968.[Crossref]
  14. Kaisho T, Akira S, , 2001. Toll-like receptors and their signaling mechanism in innate immunity. Acta Odontol Scand 59: 124130.[Crossref]
  15. Lu KC, Yang HY, Lin YF, Kao SY, Lai CH, Chu CM, Wu CC, Su SL, , 2011. The T-1237C polymorphism of the Toll-like receptor-9 gene is associated with chronic kidney disease in a Han Chinese population. Tohoku J Exp Med 225: 109116.[Crossref]
  16. Akira S, Uematsu S, Takeuchi O, , 2006. Pathogen recognition and innate immunity. Cell 124: 783801.[Crossref]
  17. Nagano Y, Kojima Y, , 1954. Immunizing property of vaccinia virus inactivated by ultraviolets rays. C R Seances Soc Biol Fil 148: 17001702.
  18. Lindenmann J, Burke DC, Isaacs A, , 1957. Studies on the production, mode of action and properties of interferon. Br J Exp Pathol 38: 551562.
  19. Pestka S, Krause CD, Walter MR, , 2004. Interferons, interferon like cytokines, and their receptors. Immunol Rev 202: 832.[Crossref]
  20. Trinchieri G, , 2010. Type I interferon: friend or foe? J Exp Med 207: 20532063.[Crossref]
  21. Liu F, Lu W, Qian Q, Qi W, Hu J, Feng B, , 2012. Frequency of TLR 2, 4, and 9 gene polymorphisms in Chinese population and their susceptibility to type 2 diabetes and coronary artery disease. J Biomed Biotechnol 2012: 373945.
  22. Yang HY, Lee HS, Lee CH, Fang WH, Chen HC, Salter DM, Su SL, , 2013. Association of a functional polymorphism in the promoter region of TLR-3 with osteoarthritis: a two-stage case-control study. J Orthop Res 31: 680685.[Crossref]
  23. Heinz S, Haehnel V, Karaghiosoff M, Schwarzfischer L, Müller M, Krause SW, Rehli M, , 2003. Species specific regulation of Toll-like receptor 3 genes in men and mice. J Biol Chem 278: 2150221509.[Crossref]
  24. Lange NE, Zhou X, Lasky-Su J, Himes BE, Lazarus R, Manuel Soto-Quirós M, Avila L, Celedón JC, Hawrylowicz CM, Raby BA, Litonjua AA, , 2011. Comprehensive genetic assessment of a functional TLR9 promoter polymorphism: no replicable association with asthma or asthma-related phenotypes. BMC Med Genet 12: 26.[Crossref]
  25. Carvalho A, Osorio NS, Saraiva M, Cunha C, Almeida AJ, Teixeira-Coelho M, Ludovico P, Pedrosa J, Pitzurra L, Aversa F, Romani L, Castro AG, , 2011. The C allele of rs5743836 polymorphism in the human TLR9 promoter links IL-6 and TLR9 up-regulation and confers increased B-cell proliferation. PLoS One 6: e28256.[Crossref]
  26. Ng MT, Van't Hof R, Crockett JC, Hope ME, Berry S, Thomson J, McLean MH, McColl KE, El-Omar EM, Hold GL, , 2010. Increase in NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9-1237T/C polymorphism is associated with Helicobacter pylori-induced gastric disease. Infect Immun 78: 13451352.[Crossref]
  27. Mostafa I, Abd el Aal M, Syam M, , 2005. HCV recurrence in adult living related transplantation: initial results of starting population. Liver Transpl 11: 456462.[Crossref]
  28. Tuite A, Gros P, , 2006. The impact of genomics on the analysis of host resistance to infectious disease. Microbes Infect 8: 16471653.[Crossref]
  29. Clementi M, Di Gianantonio E, , 2006. Genetic susceptibility to infectious diseases. Reprod Toxicol 21: 345349.[Crossref]
  30. Bedossa P, Poynard T, The METAVIR Cooperative Study Group; , 1996. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24: 289293.[Crossref]
  31. Cheng PL, Eng HL, Chou MH, You HL, Lin TM, , 2007. Genetic polymorphisms of viral infection-associated Toll-like receptors in Chinese population. Transl Res 150: 311318.[Crossref]
  32. Schröder NW, Schumann RR, , 2005. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 5: 156164.[Crossref]
  33. Turvey SE, Hawn TR, , 2006. Towards subtlety: understanding the role of Toll-like receptor signaling in susceptibility to human infections. Clin Immunol 120: 19.[Crossref]
  34. Zhou J, Huang Y, Tian D, Xu D, Chen M, Wu H, , 2009. Expression of Toll-like receptor 9 in peripheral blood mononuclear cells from patients with different hepatitis B and C viral loads. J Huazhong Univ Sci Technol 29: 313317.[Crossref]
  35. Broering R, Wu J, Meng Z, Hilgard P, Lu M, Trippler M, Szczeponek A, Gerken G, Schlaak JF, , 2008. Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol 48: 914922.[Crossref]
  36. Hu K, Wang GW, Wang ZH, , 2011. TLR9 mRNA expression and tumor necrosis factor alpha/interleukin-6 secretion in murine microglia by hepatitis C virus stimulation. Zhonghua Yi Xue Za Zhi 91: 10701074.
  37. Zhao P, Ma L, Ji H, Yu L, Feng J, Wang J, Liu MY, Jiang YF, , 2015. The expression of TLR-9, CD86, and CD95 phenotypes in circulating B cells of patients with chronic viral hepatitis B or C before and after antiviral therapy. Mediators Inflamm 2015: 762709.
  38. Wei XS, Wei CD, Tong YQ, Zhu CL, Zhang PA, , 2014. Single nucleotide polymorphisms of toll-like receptor 7 and toll-like receptor 9 in hepatitis C virus infection patients from central China. Yonsei Med J 55: 428434.[Crossref]
  39. Tanabe M, Kurita-Taniguchi M, Takeuchi K, Takeda M, Ayata M, Oyura H, Matsumoto M, Seya T, , 2003. Mechanism of up-regulation of human Toll-like receptor receptor 3 secondary to infection of measles virus-attenuated strains. Biochem Biophys Res Commun 311: 3948.[Crossref]
  40. Medhi S, Deka M, Deka P, Swargiary SS, Hazam RK, Sharma MP, Gumma PK, Asim M, Kar P, , 2011. Promoter region polymorphism and expression profile of toll like receptor-3 (TLR-3) gene in chronic hepatitis C virus (HCV) patients from India. Indian J Med Res 134: 200207.
  41. Askar E, Bregadze R, Mertens J, Schweyer S, Rosenberger A, Ramadori G, Mihm S, , 2009. TLR3 gene polymorphisms and liver disease manifestations in chronic hepatitis C. J Med Virol 81: 12041211.[Crossref]
  42. Lee YA, Wallace MC, Friedman SL, , 2015. Pathobiology of liver fibrosis: a translational success story. Gut 64: 830841.[Crossref]
  43. Seki E, Schwabe RF, , 2015. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology 61: 10661079.[Crossref]
  44. Seki E, Brenner DA, , 2008. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48: 322335.[Crossref]
  45. Szabo G, Dolganiuc A, Mandrekar P, , 2006. Pattern recognition receptors: a contemporary view on liver diseases. Hepatology 44: 287298.[Crossref]
  46. Mencin A, Kluwe J, Schwabe RF, , 2009. Toll-like receptors as targets in chronic liver diseases. Gut 58: 704720.[Crossref]
  47. Khvalevsky E, Rivkin L, Rachmilewitz J, Galun E, Giladi H, , 2007. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem 100: 13011312.[Crossref]
  48. Wang B, Trippler M, Pei R, Lu M, Broering R, Gerken G, Schlaak JF, , 2009. Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication. J Hepatol 51: 10371045.[Crossref]
  49. Xiao X, Zhao P, Rodriguez-Pinto D, Qi D, Henegariu O, Alexopoulou L, Flavell RA, Wong FS, Wen L, , 2009. Inflammatory regulation by TLR3 in acute hepatitis. J Immunol 183: 37123719.[Crossref]
  50. Nakamura M, Funami K, Komori A, Yokoyama T, Aiba Y, Araki A, Takii Y, Ito M, Matsuyama M, Koyabu M, Migita K, Taniguchi K, Fujioka H, Yatsuhashi H, Matsumoto M, Ishibashi H, Seya T, , 2008. Increased expression of Toll-like receptor 3 in intrahepatic biliary epithelial cells at sites of ductular reaction in diseased livers. Hepatol Int 2: 222230.[Crossref]
  51. Gardner T, Chen Q, Jin Y, Ajuber M, , 2010. Toll-like receptor 3 ligand dampens liver inflammation by stimulating Valpha14 invariant natural killer T cells to negatively regulate gamma/delta T cells. Am J Pathol 176: 17791789.[Crossref]
  52. Yin S, Gao B, , 2010. Toll-like receptor 3 in liver diseases. Gastroenterol Res Pract 2010: 971270.[Crossref]
  53. Dong Z, Wei H, Sun R, Hu Z, Gao B, Tian Z, , 2004. Involvement of natural killer cells in PolyI:C-induced liver injury. J Hepatolology 41: 966973.[Crossref]
  54. Jeong WI, Park O, Radaeva S, Gao B, , 2006. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 44: 14411451.[Crossref]
  55. Byun JS, Suh YG, Yi HS, Lee YS, Jeong WI, , 2013. Activation of toll-like receptor 3 attenuates alcoholic liver injury by stimulating Kupffer cells and stellate cells to produce interleukin-10 in mice. J Hepatolology 58: 342349.[Crossref]
  56. Seo W, Eun HS, Kim SY, Yi HS, Lee YS, Park SH, Jang MJ, Jo E, Kim SC, Han YM, Park KG, Jeong WI, , 2016. Exosome-mediated activation of toll-like receptor 3 in stellate cells stimulates interleukin-17 production by γδ T cells in liver fibrosis. Hepatology 64: 616631.[Crossref]
  57. Dejager L, Libert C, , 2008. Tumor necrosis factor alpha mediates the lethal hepatotoxic effects of poly(I:C) in d-galactosamine-sensitized mice. Cytokine 42: 5561.[Crossref]
  58. Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T, , 2004. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 99: 860865.[Crossref]
  59. Firdaus R, Biswas A, Saha K, Mukherjee A, Pal F, Chaudhuri S, Chandra A, Konar A, Sadhukhan PC, , 2014. Modulation of TLR 3, 7 and 8 expressions in HCV genotype 3 infected individuals: potential correlations of pathogenesis and spontaneous clearance. Biomed Res Int 2014: 491064.[Crossref]
  60. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL, , 2000. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 182: 698707.[Crossref]
  61. Dusheiko GM, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, McIntyre N, Simmonds P, , 1994. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 19: 1318.[Crossref]
  62. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK, , 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339: 14851492.[Crossref]
  63. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M, Morishima T, , 1992. Detection of hepatitis C virus by polymerase chain reaction and response to interferon alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 16: 293299.[Crossref]
  64. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH, , 1996. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med 125: 634639.[Crossref]

Data & Media loading...

  • Received : 07 Aug 2016
  • Accepted : 18 Nov 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error